Macrophage-targeting core-shell nano-drug carrier and preparation method thereof
By constructing the core of the metal organic framework nanodrug carrier and polydopamine shell, and using phosphatidylserine modification, the problem of poor targeting of macrophages is solved, the drug loading rate and delivery efficiency are improved, and high efficiency is achieved on macrophages Targeted therapy.
Patent Information
- Application Number
- CN202411149087.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-26
AI Technical Summary
The existing therapeutic drugs for macrophages have problems such as low solubility, poor targeting, and short half-life, which affect the drug delivery efficiency and therapeutic effect. The drug delivery efficiency is limited and the controlled release capacity is insufficient.
By constructing a metal organic framework nanodrug carrier core based on 2-methylimidazole and zinc ions, and forming a polydopamine shell on its surface, the targeted modification is used to form stable amide bonds, and the nanodrug carrier pairs are enhanced by using phosphatidylserine molecules to achieve targeted modification. Targeting ability of macrophages.
The drug delivery efficiency and targeting efficiency of nanodrug carriers are significantly improved, and the drug loading rate is higher than that of traditional nanodrug carriers. The stability and activity of the drug during delivery are effectively protected, avoiding early leakage and uncontrollable release.
Smart Images

Figure CN119015442A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine, and in particular relates to a macrophage-targeted core-shell metal organic framework nano drug carrier and a preparation method thereof. Background Art
[0002] Macrophages have the functions of engulfing pathogens and cell debris, presenting antigens, and secreting cytokines to regulate immune responses and promote tissue repair. They can respond to different environmental stimuli and change their phenotype to produce polarization effects, playing a key role in many diseases. For example, tumor-associated macrophages can secrete angiogenic and immunosuppressive factors, promoting tumor growth, invasion and metastasis through tissue destruction and remodeling. In addition, macrophages also play an important role in the occurrence and development of diseases such as rheumatoid arthritis, inflammatory bowel disease, and diabetes. Therefore, using macrophages as targets to treat related diseases has broad clinical application prospects. However, the current therapeutic drugs for macrophages have problems that need to be solved, such as low solubility, poor targeting, and short half-life, which seriously affect the efficiency of drug delivery and therapeutic effects. How to achieve specific and efficient delivery of therapeutic drugs while minimizing side effects is the primary challenge facing macrophage targeted therapy.
[0003] Compared with simple drugs, targeted nano drug carriers have many advantages in reducing drug toxicity, prolonging blood circulation time, enhancing targeting effect, and improving therapeutic effects. Under the action of a specific guidance mechanism, targeted nano drug carriers can selectively deliver drugs to a designated location to exert a therapeutic effect. The invention with application number 202311439811.7 discloses a nano drug carrier targeting macrophages, which induces macrophages to phagocytize nano carriers through folate receptor recognition. However, the targeting molecule folic acid used in this type of nano carrier, in addition to being expressed on macrophages, has a high expression of its receptor on the surface of polarized epithelial cells and tumor cells, and folic acid modification may reduce the targeting efficiency of nano drug carriers. In addition, conventional nano drug carriers generally have problems such as limited drug loading efficiency and insufficient controlled drug release capacity, such as the drug loading rate of mesoporous nano materials is about 25%, and the drug loading rate of liposomes and nano micelles is usually less than 10%. Therefore, enhancing the targeting ability and drug loading efficiency of nano drug carriers is the key to affecting the therapeutic effect.
[0004] Metal-organic frameworks are a type of hybrid porous material that is self-assembled from organic ligands and metal ions or clusters through coordination bonds. Compared with traditional porous materials, they have many advantages, such as ultra-low mass density (~0.13 g / cm 3 , about one tenth of mesoporous silica) and an ultra-high specific surface area (~10000m 2 / g, which is about 10 times that of mesoporous silica and mesoporous carbon). The use of metal organic framework materials as nano drug carriers provides a feasible solution for achieving efficient drug delivery. In addition, phosphatidylserine is a burial-related ligand expressed by apoptotic cells, which can be recognized by macrophages and mediate the uptake and phagocytosis of apoptotic cells by macrophages by binding to corresponding receptors in macrophages. Inspired by this, it is expected that the modification of nano drug carriers with phosphatidylserine will enhance the carrier's specific targeting ability to macrophages. Summary of the invention
[0005] The present invention aims to solve at least one of the technical problems in the related art to a certain extent. To this end, the main purpose of the present invention is to provide a core-shell nano drug carrier targeting macrophages and a preparation method thereof. The present invention achieves efficient encapsulation of water-soluble and water-insoluble drugs by constructing an organic framework nano material as a drug-carrying core; then, by constructing a polydopamine shell and using phosphatidylserine molecules to perform targeted modification on the nano drug carrier, the targeting ability of the nano drug carrier to macrophages is enhanced, thereby achieving specific targeted treatment of macrophages.
[0006] The objective of the present invention is achieved through the following technical solutions:
[0007] The macrophage-targeting core-shell nano drug carrier of the present invention is based on the metal coordination effect of 2-methylimidazole and zinc ions to construct a metal organic framework nano drug carrier core, the core has high porosity and high specific surface area, and can efficiently encapsulate various types of therapeutic drugs; secondly, by utilizing the strong adhesion characteristics of dopamine to the material interface and the oxidative self-polymerization characteristics in an alkaline environment, a polydopamine shell is formed in situ on the surface of the nano drug carrier core, and the thickness of the shell structure can be controllably adjusted by regulating the oxidative polymerization reaction conditions, thereby enhancing the protection of the internal drug and avoiding premature leakage and uncontrollable release of the drug during the delivery process; in order to give the nano drug carrier macrophage targeting ability, the EDC / NHS coupling reaction is used to activate the carboxyl group on the phosphatidylserine targeting molecule, so that it undergoes an amidation reaction with the amino group on the polydopamine shell to produce a stable amide bond, and finally a nano drug carrier with macrophage-specific targeting ability is prepared.
[0008] Specifically, a method for preparing a macrophage-targeting core-shell nano drug carrier comprises the following steps:
[0009] 1) dissolving the zinc salt and the therapeutic drug in a methanol solution, and subjecting the solution to ultrasonic vibration to obtain a mixed solution A after the solution is completely dissolved;
[0010] 2) dissolving 2-methylimidazole in the methanol solution, and subjecting it to ultrasonic vibration to obtain a mixed solution B after it is completely dissolved;
[0011] 3) The solution B is quickly added to the solution A, and the zinc salt and 2-methylimidazole are reacted in different molar ratios, and the reaction is carried out on a constant temperature oscillator, and the reaction solution is centrifuged and washed with ultrapure water for multiple times to obtain the nano drug carrier core;
[0012] 4) dissolving dopamine hydrochloride in ultrapure water and adjusting the pH value to 8-8.5 to obtain a dopamine hydrochloride solution;
[0013] 5) adding the dopamine solution prepared in step 4) to the nano drug carrier core in step 3), performing an oxidative polymerization reaction after magnetic stirring, centrifuging the obtained solution, and washing it with ultrapure water for multiple times to obtain a core-shell nano drug carrier;
[0014] 6) Dissolve EDC and NHS in ultrapure water, add phosphatidylserine, dissolve by ultrasonication, and react by magnetic stirring for 10-15h;
[0015] 7) The obtained solution was centrifuged at 2000 rpm to remove unreacted phosphatidylserine, and then centrifuged again at 10000 rpm, and washed with ultrapure water for multiple times to obtain a core-shell nano drug carrier targeting macrophages.
[0016] In certain specific embodiments, the zinc salt is one or more of anhydrous zinc acetate, dihydrate zinc acetate, zinc chloride, and hexahydrate zinc nitrate.
[0017] In certain specific embodiments, the therapeutic drug includes a water-soluble drug or a water-insoluble drug, the water-soluble drug is one or two of rifampicin, metformin, and doxorubicin, and the water-insoluble drug is one or two of curcumin, triptolide, and Mdivi-1 inhibitor.
[0018] In some specific embodiments, the mass concentration of the methanol solution in step 1 and step 2) is 40-60%
[0019] In certain specific embodiments, the reaction molar ratio of 2-methylimidazole and zinc salt in step 3) is (10-100):1.
[0020] In certain specific embodiments, the reaction conditions in step 3) are: continuing the reaction at 20-30° C. and 100-150 rpm for 10-15 hours.
[0021] In certain specific embodiments, the concentration of the dopamine hydrochloride solution is 0.1-10 mg / ml.
[0022] In certain specific embodiments, the oxidative polymerization reaction conditions in step 5) are: reacting at 20-30° C. for 0.5-6 h.
[0023] In certain specific embodiments, the reaction molar ratio of EDC, NHS and phosphatidylserine is 1:0.8:0.1-0.7.
[0024] A core-shell nano drug carrier targeting macrophages is prepared by the above-mentioned preparation method.
[0025] Compared with the prior art, the present invention has at least the following advantages:
[0026] 1) The macrophage-targeted core-shell nano drug carrier of the present invention has high porosity and high specific surface area, can efficiently encapsulate water-soluble drugs and water-insoluble drugs, and has a drug loading rate of more than 90% for water-soluble drugs and more than 80% for water-insoluble drugs, which is much higher than that of traditional nano drug carriers, and significantly improves the drug delivery efficiency of nano drug carriers.
[0027] 2) Based on the strong interfacial adhesion and oxidative self-polymerization properties of dopamine, the present invention forms a polydopamine shell structure with adjustable thickness in situ on the surface of the organic framework nanomaterial. The size of the core-shell structure can be adjusted as needed, effectively protecting the stability and activity of the drug and avoiding premature leakage and uncontrolled release of the drug during the delivery process.
[0028] 3) Based on the EDC / NHS coupling reaction, the present invention grafts the phosphatidylserine targeting molecule onto the polydopamine shell through an amidation reaction, and constructs a macrophage-specific targeted nanodrug carrier. The cumulative efficiency in the cell is about 4.7 times that of the nanodrug carrier without targeted modification, which significantly improves the targeting efficiency and intracellular delivery efficiency of the nanodrug carrier. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] In order to more clearly illustrate the specific embodiments of the present invention, the drawings required for use in the specific embodiments or the description of the prior art will be briefly introduced below.
[0030] Figure 1 Schematic diagram of the preparation process of macrophage-targeted nanodrug carriers;
[0031] Figure 2 This is the transmission electron microscopy morphology of the thin-shell structure nano drug carrier;
[0032] Figure 3 This is the particle size distribution diagram of the thin-shell structure nano drug carrier with an average particle size of 98nm;
[0033] Figure 4 This is the transmission electron microscopy morphology of the thick-shell structured nano drug carrier;
[0034] Figure 5 This is the particle size distribution diagram of the thick-shell nano drug carrier with an average particle size of 127 nm;
[0035] Figure 6 This is a bright field image of nano-drug carriers targeting macrophages;
[0036] Figure 7 Fluorescence image of nano drug carrier targeting macrophages;
[0037] Figure 8 is the accumulation of nano drug carriers in macrophages;
[0038] Fig. 9 The targeting efficiency of nanodrug carriers to macrophages. DETAILED DESCRIPTION
[0039] The present invention will be further described in detail below in conjunction with the accompanying drawings and embodiments. The following embodiments are only illustrative and not restrictive, and the protection scope of the present invention cannot be limited thereto.
[0040] When a certain amount, concentration or other value or parameter is expressed in the form of a range, a preferred range, or a preferred upper and lower numerical limit, it should be understood that it is equivalent to specifically revealing any range by combining any pair of upper range limits or preferred numerical values with any lower range limit or preferred numerical value, regardless of whether the range is specifically disclosed. Unless otherwise indicated, the numerical range values listed herein include the endpoints of the range, and all integers and fractions within the range.
[0041] Unless otherwise indicated, all percentages, parts, ratios, etc. herein are by weight.
[0042] The materials, methods, and examples herein are illustrative and are not to be construed as limiting unless specifically stated.
[0043] In the following examples, the macrophages used were purchased from Wuhan Pronocell Life Science Co., Ltd.; the zinc salt, 2-methylimidazole and dopamine hydrochloride used were all analytical grade or above, and the molecular weight of the phosphatidylserine used was in the range of 1000 to 5000 Da;
[0044] The test methods used in the following embodiments include:
[0045] The synthesis and targeting performance are reflected by testing the main properties of each test sample respectively; the main properties tested in this application include drug loading, targeted accumulation, targeting efficiency, etc.
[0046] 1) Drug loading test;
[0047] The characteristic absorption spectrum of the drug was detected by using an ultraviolet-visible spectrophotometer and a high performance liquid chromatograph, and the drug loading amount was calculated by drawing a standard curve of drug concentration and absorbance according to the formula: drug loading amount = drug amount in the nano drug carrier / total mass of the nano drug carrier × 100%;
[0048] 2) Morphology test
[0049] The nano drug carrier suspension was ultrasonically dispersed and then dripped onto the sample preparation copper grid. After the copper grid was fully dried, the morphology and particle size of the sample were tested using a transmission electron microscope.
[0050] 3) Targeted cumulative testing
[0051] The nanomaterials were fluorescently labeled, and the cell morphology and intracellular accumulation of nanodrug carriers were tested using the bright field mode and fluorescence field mode of a laser confocal microscope;
[0052] 4) Targeting efficiency test
[0053] The present invention provides a method for preparing a macrophage-targeting core-shell metal organic framework nano drug carrier, the method flow is as follows: Figure 1 As shown, the raw materials used have good biocompatibility. The nano drug carrier uses metal organic framework nanomaterials as the core, which can efficiently encapsulate water-soluble drugs and water-insoluble drugs. By utilizing the strong adhesion properties of dopamine, a polydopamine protective layer with adjustable thickness is formed on the surface of the core-shell nano drug carrier. On the one hand, it effectively protects the activity of therapeutic drugs and avoids premature leakage during drug delivery; on the other hand, it provides modification sites for macrophages to molecule phosphatidylserine, and forms a stable amide bond between the carboxyl group on the phosphatidylserine molecule and the amino group on the polydopamine shell, ultimately giving the nano drug carrier specific targeting ability to macrophages.
[0054] Example 1
[0055] This embodiment provides a method for preparing a macrophage-targeted core-shell nanoparticle drug carrier, which comprises the following steps:
[0056] 1) Dissolve anhydrous zinc acetate and rifampicin in 5 mL of 60% methanol solution, and ultrasonically vibrate for 10 min to obtain a mixed solution A after they are completely dissolved;
[0057] 2) Dissolve 2-methylimidazole in 5 mL of 60% methanol solution and ultrasonically vibrate for 10 min to obtain a mixed solution B after it is completely dissolved;
[0058] 3) The above solution B was quickly added to solution A, 2-methylimidazole and anhydrous zinc acetate were reacted at a molar ratio of 100:1, placed on a constant temperature oscillator, and continued to react for 12 hours at 25° C. and 120 rpm. The reaction solution was centrifuged at a speed of 10,000 rpm, and washed three times with ultrapure water to obtain a nano drug carrier core;
[0059] 4) dissolving 0.1 mg of dopamine hydrochloride in 20 mL of ultrapure water, and adjusting the pH of the dopamine solution to 8-8.5 using 1 mol / L NaOH solution and 1 mol / L HCl solution to obtain a dopamine hydrochloride solution;
[0060] 5) adding the dopamine hydrochloride solution in step 4) to the nano drug carrier core in step 3), stirring with magnetic force, reacting at 25° C. for 0.5 h, centrifuging the obtained solution at 10,000 rpm, and washing three times with ultrapure water to obtain a core-shell nano drug carrier;
[0061] 6) Dissolve EDC and NHS in 5 mL of ultrapure water, add phosphatidylserine, the molar ratio of the three (EDC, NHS and phosphatidylserine) is 1:0.8:0.1, dissolve by ultrasound, and react with magnetic stirring for 12 h;
[0062] 7) The obtained solution was centrifuged at 2000 rpm to remove unreacted phosphatidylserine, and then centrifuged at 10000 rpm, and washed three times with ultrapure water to obtain a core-shell nano drug carrier targeting macrophages.
[0063] Example 2
[0064] This embodiment provides a method for preparing a macrophage-targeted core-shell nano drug carrier, which comprises the following steps:
[0065] 1) Dissolve zinc acetate dihydrate and doxorubicin together in 5 mL of 60% methanol solution, and ultrasonically vibrate for 10 min to obtain a mixed solution A after they are completely dissolved;
[0066] 2) Dissolve 2-methylimidazole in 5 mL of 60% methanol solution and ultrasonically vibrate for 10 min to obtain a mixed solution B after it is completely dissolved;
[0067] 3) The above solution B was quickly added to solution A, 2-methylimidazole and zinc acetate dihydrate were reacted at a molar ratio of 70:1, placed on a constant temperature oscillator, and continued to react for 12 hours at 25° C. and 120 rpm. The reaction solution was centrifuged at 10,000 rpm and washed three times with ultrapure water to obtain a nano drug carrier core;
[0068] 4) dissolving 2 mg of dopamine hydrochloride in 20 mL of ultrapure water, and adjusting the pH of the dopamine solution to 8-8.5 using 1 mol / L NaOH solution and 1 mol / L HCl solution to obtain a dopamine hydrochloride solution;
[0069] 5) adding the dopamine hydrochloride solution in step 4) to the nano drug carrier core in step 3), stirring with magnetic force, reacting at 25° C. for 2 h, centrifuging the obtained solution at 10,000 rpm, and washing three times with ultrapure water to obtain a core-shell nano drug carrier;
[0070] 6) Dissolve EDC and NHS in 5 mL of ultrapure water, add phosphatidylserine, the molar ratio of the three (EDC, NHS and phosphatidylserine) is 1:0.8:0.3, dissolve by ultrasound, and react with magnetic stirring for 12 h;
[0071] 7) The obtained solution was centrifuged at 2000 rpm to remove unreacted phosphatidylserine, and then centrifuged at 10000 rpm. After washing three times with ultrapure water, a core-shell nano drug carrier targeting macrophages was obtained, and the drug loading rate was 90%.
[0072] Example 3
[0073] This embodiment provides a method for preparing a macrophage-targeted core-shell metal organic framework nano drug carrier, which comprises the following steps:
[0074] 1) Dissolve zinc chloride in 5 mL of 60% methanol solution, dissolve triptolide in 20 μL of DMSO, add the mixture to the methanol solution, and shake with ultrasound for 10 min to obtain a mixed solution A after the mixture is completely dissolved;
[0075] 2) Dissolve 2-methylimidazole in 5 mL of 60% methanol solution and ultrasonically vibrate for 10 min to obtain a mixed solution B after it is completely dissolved;
[0076] 3) The above solution B was quickly added to solution A, 2-methylimidazole and zinc chloride were reacted at a molar ratio of 30:1, placed on a constant temperature oscillator, and the reaction was continued for 12 hours at 25° C. and 120 rpm. The reaction solution was centrifuged at a speed of 10,000 rpm, and washed three times with ultrapure water to obtain a nano drug carrier core;
[0077] 4) dissolving 5 mg of dopamine hydrochloride in 20 mL of ultrapure water, and adjusting the pH of the dopamine solution to 8-8.5 using 1 mol / L NaOH solution and 1 mol / L HCl solution to obtain a dopamine hydrochloride solution;
[0078] 5) adding the dopamine hydrochloride solution in step 4) to the nano drug carrier core in step 3), stirring with magnetic force, reacting at 25° C. for 4 h, centrifuging the obtained solution at 10,000 rpm, and washing three times with ultrapure water to obtain a core-shell nano drug carrier;
[0079] 6) Dissolve EDC and NHS in 5 mL of ultrapure water, add phosphatidylserine, the molar ratio of the three (EDC, NHS and phosphatidylserine) is 1:0.8:0.5, dissolve by ultrasound, and react with magnetic stirring for 12 h;
[0080] 7) The obtained solution was centrifuged at 2000 rpm to remove unreacted phosphatidylserine, and then centrifuged at 10000 rpm, and washed three times with ultrapure water to obtain a core-shell nano drug carrier targeting macrophages.
[0081] Example 4
[0082] This embodiment provides a method for preparing a macrophage-targeted core-shell metal organic framework nano drug carrier, which comprises the following steps:
[0083] 1) Dissolve zinc nitrate hexahydrate in 5 mL of 60% methanol solution, dissolve Mdivi-1 inhibitor in 30 μL of DMSO, add the mixture to the methanol solution, and ultrasonically shake for 10 minutes to obtain a mixed solution A after the mixture is completely dissolved;
[0084] 2) Dissolve 2-methylimidazole in 5 mL of 60% methanol solution and ultrasonically vibrate for 10 min to obtain a mixed solution B after it is completely dissolved;
[0085] 3) The above solution B was quickly added to the solution A, 2-methylimidazole and zinc nitrate hexahydrate were reacted at a molar ratio of 10:1, placed on a constant temperature oscillator, and continued to react for 12 hours at 25° C. and 120 rpm. The reaction solution was centrifuged at 10,000 rpm, and washed three times with ultrapure water to obtain the nano drug carrier core;
[0086] 4) dissolving 10 mg of dopamine hydrochloride in 20 mL of ultrapure water, and adjusting the pH of the dopamine solution to 8-8.5 using 1 mol / L NaOH solution and 1 mol / L HCl solution to obtain a dopamine hydrochloride solution;
[0087] 5) adding the dopamine hydrochloride solution in step 4) to the nano drug carrier core in step 3), stirring with a magnetic stir, reacting at 25° C. for 6 h, centrifuging the obtained solution at a speed of 10,000 rpm, and washing three times with ultrapure water to obtain a core-shell nano drug carrier;
[0088] 6) Dissolve EDC and NHS in 5 mL of ultrapure water, add phosphatidylserine, the molar ratio of the three (EDC, NHS and phosphatidylserine) is 1:0.8:0.7, dissolve by ultrasound, and react with magnetic stirring for 12 h;
[0089] 7) The obtained solution was centrifuged at 2000 rpm to remove unreacted phosphatidylserine, and then centrifuged at 10000 rpm. After washing three times with ultrapure water, a core-shell nano drug carrier targeting macrophages was obtained, and the drug loading rate was 85%.
[0090] Example 5
[0091] This embodiment provides a method for preparing a macrophage-targeted core-shell metal organic framework nano drug carrier, which comprises the following steps:
[0092] 1) Dissolve zinc acetate dihydrate, rifampicin and metformin together in 5 mL of 60% methanol solution, and ultrasonically vibrate for 10 min to obtain a mixed solution A after they are completely dissolved;
[0093] 2) Dissolve 2-methylimidazole in 5 mL of 60% methanol solution and ultrasonically vibrate for 10 min to obtain a mixed solution B after it is completely dissolved;
[0094] 3) The above solution B was quickly added to solution A, 2-methylimidazole and zinc acetate dihydrate were reacted at a molar ratio of 50:1, placed on a constant temperature oscillator, and continued to react for 12 hours at 25° C. and 120 rpm. The reaction solution was centrifuged at 10,000 rpm and washed three times with ultrapure water to obtain a nano drug carrier core;
[0095] 4) dissolving 1 mg of dopamine hydrochloride in 20 mL of ultrapure water, and adjusting the pH of the dopamine solution to 8-8.5 using 1 mol / L NaOH solution and 1 mol / L HCl solution to obtain a dopamine hydrochloride solution;
[0096] 5) adding the dopamine solution in step 4) to the nano drug carrier core in step 3), stirring with magnetic force, reacting at 25° C. for 2 h, centrifuging the obtained solution at 10,000 rpm, and washing three times with ultrapure water to obtain a core-shell nano drug carrier;
[0097] 6) Dissolve EDC and NHS in 5 mL of ultrapure water, add phosphatidylserine, the molar ratio of the three (EDC, NHS and phosphatidylserine) is 1:0.8:0.7, dissolve by ultrasound, and react with magnetic stirring for 12 h;
[0098] 7) The obtained solution was centrifuged at 2000 rpm to remove unreacted phosphatidylserine, and then centrifuged at 10000 rpm, and washed three times with ultrapure water to obtain a core-shell nano drug carrier targeting macrophages.
[0099] Comparative Example 1 (Nano drug carrier without targeted modification)
[0100] This comparative example provides a method for preparing a macrophage-targeted core-shell metal organic framework nano drug carrier, which is basically the same as Example 1, except that after the core-shell nano drug carrier is prepared, the phosphatidylserine targeting molecule is not used to modify the surface of the nano drug carrier. The prepared core-shell nano drug carrier lacks the ability to target macrophages due to the lack of modification of macrophage targeting recognition molecules, resulting in a significant reduction in the accumulation of non-targeted modified core-shell nano drug carriers in macrophages.
[0101] Performance test case
[0102] The present invention performs performance tests on the prepared core-shell nano drug carrier, specifically:
[0103] 1) Appearance
[0104] 1.1) The present application tests the appearance morphology of the core-shell nano drug carrier prepared in Example 2, and the transmission electron microscopy morphology thereof is shown in FIG. Figure 2 As shown, from Figure 2 It can be seen that the core-shell nano drug carrier has an obvious core-shell structure, and its shell thickness is about 15 nm. It can be observed that polydopamine is evenly coated on the surface of the organic framework nano material.
[0105] 1.2) The present invention also tests the particle size of the core-shell nano drug carrier prepared in Example 2, and the particle size distribution is as follows: Figure 3 As shown in the figure, it can be seen that the particle size of the core-shell nano drug carrier is normally distributed, and the average particle size is about 98nm, which is conducive to being recognized and phagocytosed by macrophages.
[0106] 1.3) The present application tested the appearance morphology of the core-shell nano drug carrier prepared in Example 4, and the transmission electron microscopy morphology thereof is shown in FIG. Figure 4 As shown, from Figure 4 It can be seen that the shell layer thickness of the core-shell nanodrug carrier is about 36nm, which means that by adjusting the reaction conditions, nanodrug carriers with different shell thicknesses can be prepared. Thicker shells can meet more application needs, better protect the activity of therapeutic drugs, and prolong the release time of drugs.
[0107] 14) The present invention also tests the particle size of the core-shell nano drug carrier prepared in Example 4, and the particle size distribution is as follows: Figure 5As shown in the figure, it can be seen that the particle size of the core-shell nano drug carrier is normally distributed, and the average particle size is about 127nm, which is conducive to being recognized and phagocytosed by macrophages.
[0108] 2) Testing of targeting performance of core-shell nanodrug carriers
[0109] 2.1) In order to clarify the targeting characteristics of the nano drug carrier of the present invention to macrophages, the nano drug carrier was co-incubated with macrophages. Taking the core-shell nano drug carrier prepared in Example 4 as an example, the phagocytosis of the nano drug carrier by cells was observed under the bright field mode of a microscope. The bright field image is as follows: Figure 6 As shown, the results in the figure show a large accumulation of core-shell nanodrug carriers in macrophages, as indicated by the black arrows in the figure.
[0110] 2.2) To further demonstrate the accumulation of nano drug carriers in cells, the fluorescence mode was used to observe the fluorescently labeled core-shell nano drug carriers. Figure 7 As shown, the results in the figure show that the core-shell nanodrug carriers co-localize with macrophages and accumulate in large quantities inside the macrophages, as indicated by the white arrows in the figure.
[0111] 2.3) The present application tests the accumulation of the targeted modified core-shell nano drug carrier of Example 4 and the non-targeted modified core-shell nano drug carrier prepared in Comparative Example 1 in macrophages. Specifically, the non-targeted modified core-shell nano drug carrier and the targeted modified core-shell nano drug carrier are co-incubated with macrophages at the same concentration, and then the accumulation of the core-shell nano drug carrier in macrophages is tested by laser confocal microscopy. The results are as follows: Figure 8 As shown in the figure, it can be seen that the nano drug carrier after targeted modification efficiently targets macrophages and accumulates in large quantities in macrophages.
[0112] 2.4) The present application tests the targeting efficiency of the targeted modified core-shell nano drug carrier of Example 4 and the non-targeted modified core-shell nano drug carrier prepared in Comparative Example 1 in macrophages, and evaluates the targeting efficiency of the nano drug carrier to macrophages by statistically analyzing the average fluorescence intensity of the cells in the fluorescence image; the results are as follows: Fig. 9 As shown, from Fig. 9 It can be seen that compared with the non-targeted modified nanodrug carriers, the targeted modified nanodrug carriers showed efficient targeting ability to macrophages, and the intracellular accumulation efficiency was 4.7 times that of the non-targeted nanodrug carriers.
[0113] In summary: compared with the prior art, the targeted nano drug carrier of the present invention has convenient synthesis steps, is easy to prepare and expand production on a large scale, the synthesized nano drug carrier has uniform particle size, and the microstructure can be regulated as needed. By modifying the phosphatidylserine molecules on the surface of the nano drug carrier, it has efficient macrophage targeting ability and is more easily recognized and phagocytosed by macrophages, thereby enhancing the accumulation of nano drug carriers in macrophages, achieving efficient delivery of therapeutic drugs, and effectively enhancing the therapeutic effect of drugs.
[0114] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. These modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be included in the scope of the claims and specification of the present invention.
Claims
1. A method for preparing a core-shell nano drug carrier targeting macrophages, characterized in that: The steps include: 1) dissolving the zinc salt and the therapeutic drug in a methanol solution, and subjecting the solution to ultrasonic vibration to obtain a mixed solution A after the solution is completely dissolved; 2) dissolving 2-methylimidazole in the methanol solution, and subjecting it to ultrasonic vibration, until it is completely dissolved to obtain a mixed solution B; 3) The solution B is quickly added to the solution A, and the zinc salt and 2-methylimidazole are reacted in different molar ratios, and the reaction is carried out on a constant temperature oscillator, and the reaction solution is centrifuged and washed with ultrapure water for multiple times to obtain the nano drug carrier core; 4) dissolving dopamine hydrochloride in ultrapure water and adjusting the pH value to 8-8.5 to obtain a dopamine hydrochloride solution; 5) adding the dopamine solution prepared in step 4) to the nano drug carrier core in step 3), performing an oxidative polymerization reaction after magnetic stirring, centrifuging the obtained solution, and washing it with ultrapure water for multiple times to obtain a core-shell nano drug carrier; 6) Dissolve EDC and NHS in ultrapure water, add phosphatidylserine, dissolve by ultrasonication, and react by magnetic stirring for 10-15 hours; 7) The obtained solution was centrifuged at 2000 rpm to remove unreacted phosphatidylserine, and then centrifuged again at 10000 rpm, and washed with ultrapure water for multiple times to obtain a core-shell nano drug carrier targeting macrophages.
2. The method for preparing the macrophage-targeting core-shell nano drug carrier according to claim 1, characterized in that: The zinc salt is one or more of anhydrous zinc acetate, dihydrate zinc acetate, zinc chloride, and hexahydrate zinc nitrate.
3. The method for preparing the macrophage-targeting core-shell nano drug carrier according to claim 2, characterized in that: The therapeutic drugs include water-soluble drugs or water-insoluble drugs. The water-soluble drugs are one or two of rifampicin, metformin, and doxorubicin. The water-insoluble drugs are one or two of curcumin, triptolide, and Mdivi-1 inhibitor.
4. The method for preparing the macrophage-targeting core-shell nano drug carrier according to claim 1, characterized in that: The reaction molar ratio of 2-methylimidazole and zinc salt in step 3) is (10-100):
1.
5. The method for preparing the macrophage-targeting core-shell nano drug carrier according to claim 4, characterized in that: The reaction conditions in step 3) are: continuing the reaction at 20-30°C and 100-150 rpm for 10-15 hours.
6. The method for preparing the macrophage-targeting core-shell nano drug carrier according to claim 1, characterized in that: The concentration of the dopamine hydrochloride solution is 0.1-10 mg / ml.
7. The method for preparing the macrophage-targeting core-shell nano drug carrier according to claim 6, characterized in that: The oxidative polymerization reaction conditions in step 5) are: reaction at 20-30° C. for 0.5-6 h.
8. The method for preparing the macrophage-targeting core-shell nano drug carrier according to claim 7, characterized in that: The reaction molar ratio of EDC, NHS and phosphatidylserine is 1:0.8:0.1-0.
7.
9. A core-shell nano drug carrier targeting macrophages, characterized in that: The method is prepared by the method according to any one of claims 1 to 8.
Citation Information
Patent Citations
Nano-drug for regulating macrophage M2 type polarization by targeting mitochondria as well as preparation method and application of nano-drug
CN117797268A
Cited By
Intelligent packaging film based on multilayer packaging nanocomposite and preparation method of intelligent packaging film
CN122036996A
